Funding for mitochondrial biology firm
NRG Therapeutics, a privately-held UK-based neuroscience company targeting mitochondrial dysfunction, has received a Biomedical Catalyst (BMC) award from the UK government.
This £2.68 million ($3.39 million) award will fund pre-clinical development of the company’s novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND)/amyotrophic lateral sclerosis and other debilitating chronic neurodegenerative disorders.
"With our unique discoveries, NRG is in a leadership position in this field to develop first-in-class CNS-penetrant mPTP inhibitors"NRG is applying science in the field of mitochondrial biology to develop first-in-class treatments for Parkinson’s, MND and, potentially, other neurodegenerative disorders.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze